In a report released today, Kelly Shi from Jefferies maintained a Buy rating on Connect Biopharma Holdings (CNTB – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $1.11.
According to TipRanks, Shi is an analyst with an average return of -25.4% and a 22.22% success rate. Shi covers the Healthcare sector, focusing on stocks such as CTI BioPharma, PTC Therapeutics, and ImmunityBio.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings with a $5.92 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $23.48 and a one-year low of $0.56. Currently, Connect Biopharma Holdings has an average volume of 314.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.
Read More on CNTB:
- CORRECTING and REPLACING — Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
- Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
- Connect Biopharma price target raised to $1.75 from $1.50 at Piper Sandler
- Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update
